Sertraline vs Duloxetine: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Sertraline selectively inhibits the serotonin transporter (SLC6A4), increasing synaptic serotonin that consumes folate through BH4-dependent synthesis pathways, disrupts serotonin-to-melatonin pineal conversion, and triggers SIADH-mediated sodium wasting. CTD documents 138 gene interactions for sertraline — moderate breadth among SSRIs. As a pure SSRI without norepinephrine effects, sertraline avoids the additional magnesium depletion that dual-action agents cause.
Sertraline has 44% bioavailability with a 26-hour half-life and 98.5% protein binding, providing stable once-daily dosing with predictable blood levels.
- ✓Only 3 nutrients depleted — lighter depletion burden than duloxetine's 4
- ✓No magnesium depletion — avoids the cardiovascular and neurological risks of Mg loss
- ✓ChEMBL documents extensive RCT data across depression, OCD, PTSD, panic, and social anxiety
- ✓26-hour half-life provides smooth blood levels with manageable discontinuation
- ✗No FDA pain indication — cannot replace duloxetine for patients with depression plus chronic pain
- ✗98.5% protein binding creates displacement interaction risks with highly-bound co-medications
- ✗FAERS logs 67,356 adverse event reports reflecting widespread prescribing
- ✗138 CTD gene interactions indicate moderate off-target molecular effects
Patients with depression, anxiety disorders, or PTSD who don't have chronic pain comorbidity and want the lightest possible nutrient depletion burden from antidepressant therapy.
Duloxetine inhibits both serotonin (SLC6A4) and norepinephrine (SLC6A2) reuptake, creating the same three SSRI-class depletions as sertraline plus an additional magnesium burden from increased catecholamine turnover. The norepinephrine pathway acceleration consumes B-vitamin cofactors more broadly than serotonin alone and increases magnesium demand through COMT-mediated catecholamine metabolism. CTD documents 16 gene interactions — fewer than sertraline's 138, but the dual-action mechanism depletes one additional nutrient.
Duloxetine achieves 50% bioavailability with a 12-hour half-life and 90% protein binding, typically dosed once or twice daily depending on the indication.
- ✓FDA-approved for fibromyalgia, diabetic neuropathy, and chronic musculoskeletal pain — unique pain indications
- ✓Only 16 CTD gene interactions versus sertraline's 138 — narrower off-target molecular profile
- ✓12-hour half-life creates gentler discontinuation than venlafaxine's notorious 5-hour
- ✓Dual SNRI mechanism provides broader symptom relief for patients with depression plus pain
- ✗4 nutrients depleted versus sertraline's 3 — additional magnesium loss adds cardiovascular risk
- ✗Cannot be opened or crushed — enteric coating is essential, limiting dose titration flexibility
- ✗Higher cost than generic sertraline for patients without pain comorbidity
- ✗90% protein binding still creates displacement interaction risks, though less than sertraline's 98.5%
Patients with depression plus chronic pain conditions (fibromyalgia, neuropathy, musculoskeletal) who accept the additional magnesium depletion for dual symptom relief.
Feature Comparison
| Feature | Sertraline | Duloxetine |
|---|---|---|
| Drug Class | SSRI (pure serotonin) | SNRI (serotonin + norepinephrine) |
| Nutrients Depleted | 3 — sodium, folate, melatonin | 4 — sodium, B vitamins, magnesium, melatonin |
| CTD Gene Interactions | 138 documented | 16 documented |
| Half-Life | 26 hours | 12 hours |
| Protein Binding | 98.5% | 90% |
| Pain Indications | None (off-label only) | FDA: fibromyalgia, neuropathy, MSK pain |
| FAERS Reports | 67,356 total | 109 total |
| Magnesium Impact | No depletion | Depleted (NE turnover) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
This comparison pits SSRI simplicity against SNRI breadth. Sertraline depletes only 3 nutrients with no magnesium impact — the lighter pharmacological footprint for patients whose sole diagnosis is depression or anxiety. Duloxetine depletes 4 nutrients including magnesium but offers FDA-approved pain indications that sertraline simply can't match. For patients with depression plus fibromyalgia, diabetic neuropathy, or chronic musculoskeletal pain, duloxetine's additional magnesium depletion is an acceptable cost for dual symptom coverage. CTD data reveals an interesting reversal: sertraline has 138 gene interactions versus duloxetine's 16, meaning sertraline has a broader off-target molecular profile despite depleting fewer nutrients. For pure depression without pain, sertraline's lighter depletion burden wins. For depression-plus-pain, duloxetine's unique indications justify the additional supplement.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 138 gene interactions for sertraline; 16 for duloxetine including SNRI-specific noradrenergic targets
- [2]ChEMBL bioactivity database: extensive RCT data for sertraline across 5 indications; duloxetine data across depression and 3 FDA pain indications
- [3]FAERS (FDA Adverse Event Reporting System): 67,356 sertraline reports; 109 duloxetine reports
- [4]PharmGKB pharmacogenomics database: CYP2D6 annotations for both drugs; ABCB1 transporter variant effects
- [5]PubMed PMID 22849956 — Fava GA et al. Withdrawal symptoms after SSRI and SNRI discontinuation. Psychotherapy and Psychosomatics. 2015;84(2):72-81
Check your medications
Check Free →